Joseph Brandwein
Joseph Brandwein is an expert in Hematology at University of Alberta (Canada). As of October 2026, ScienceLeadR ranks Joseph Brandwein in the top 1% of experts worldwide for Leukemia. Joseph Brandwein has authored 291 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 8 of them ongoing. SLR score: 1,306 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 291
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Subcutaneous Blinatumomab Plus Ponatinib for BCR ABL B ALL NCT07301424 — burkitt lymphoma, skin, cells, precursor cell lymphoblastic leukemia-lymphoma, blood, dasatinib, pharmaceutical preparations, genes, abl, lymphoma, leukemia, tablets, therapeutics, chromosomes, philadelphia chromosome, mutation, b-lymphocytes | Phase 2 | Not yet recruiting | 2027 |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy NCT06384261 — genes, bcl-2, pharmaceutical preparations, leukemia, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, antibodies, monoclonal, therapeutics | Phase 2 | Active not recruiting | 2024 |
| MYELOMATCH A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) NCT05564390 — injections, cells, research design, guidelines as topic, epoetin alfa, myelodysplastic syndromes, genetic testing, alanine, bone marrow, blood, microscopy, electron, scanning transmission, radionuclide angiography, hematopoietic stem cell transplantation, gemtuzumab, pharmaceutical preparations, tomography, whole-body irradiation, melphalan, heart, liposomes, positron-emission tomography, practice guidelines as topic, neoplasms, multiple chronic conditions, drug combinations, gated blood-pool imaging, cytarabine, transplantation, homologous, decitabine, leukemia, stem cells, angiography, tablets, biopsy, phenylalanine, radiography, leukemia, myeloid, acute, biomarkers, azacitidine, leukemia, myeloid, genes, arac, receptors, interleukin-1, interleukin-1, echocardiography, antibodies, monoclonal, daunorubicin, mechlorethamine, specimen handling, myeloproliferative disorders, therapeutics, neural tube defects, cell transplantation, stem cell transplantation, busulfan, esters, pyrimidinones, hematopoietic stem cells, interleukin-1 receptor-associated kinases, mutation, transplantation, radionuclide ventriculography, cytosine, bone and bones | Phase 2 | Recruiting | 2024 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) NCT05554406 — injections, cells, research design, growth, bone marrow, blood, radionuclide angiography, heart, liposomes, neoplasms, multiple chronic conditions, gated blood-pool imaging, cytarabine, leukemia, angiography, leukemia, myeloid, acute, aged, azacitidine, leukemia, myeloid, genes, arac, work, echocardiography, daunorubicin, specimen handling, myeloproliferative disorders, therapeutics, neural tube defects, pyrimidinones, radionuclide ventriculography, cytosine, bone and bones | Phase 2 | Recruiting | 2024 |
| Comparing Cytarabine Daunorubicin Therapy Versus Cytarabine Daunorubicin Venetoclax Versus Venetoclax Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) NCT05554393 — cells, growth, bone marrow, blood, radionuclide angiography, pharmaceutical preparations, heart, neoplasms, multiple chronic conditions, gated blood-pool imaging, cytarabine, leukemia, angiography, drug therapy, leukemia, myeloid, acute, azacitidine, enzymes, leukemia, myeloid, echocardiography, daunorubicin, specimen handling, therapeutics, dna, pyrimidinones, radionuclide ventriculography, cytosine, chemotherapy, bone and bones | Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map